Abbreviations: CI ϭ confidence interval; HAART ϭ highly active antiretroviral therapy; RR ϭ relative risk R hodococcus equi, previously known as Corynebacterium equi, is a weak, acid-fast, Grampositive rod. It is currently classified among the nocardiform actinomycetes. 1 The ability of R equi to remain inside macrophages and even destroy them is considered to be the basis for its pathogenicity.
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Manuscript received June 19, 2002 ; revision accepted October 8, 2002 . Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (e-mail: permissions@chestnet.org). macrophages with periodic acid-Schiff-positive granular cytoplasm. Occasionally, a peculiar histopathologic lesion is observed, known as malakoplakia, which is characterized by histiocytes with cytoplasmic inclusions laminated with iron and calcium (Michaelis-Gutmann bodies 2,4 -6 ). It grows well in ordinary culture media and forms salmon-pink colored colonies. 1,2,6 R equi is a common pathogen of pneumonia in foals and sometimes produces infections in other mammals. 1, 2 Although natural exposure to R equi is frequent, 7 the first infection by this organism in humans was described in 1967. 8 It mainly affects immunocompromised patients, especially those with HIV infection. 9, 10 Although it could be underdiagnosed in the past, 2, 11 and despite some reports that have detected an increasing incidence, 9 it is a very uncommon illness, both in general population and in patients with HIV infection. It has been reported only in isolated cases or in short series with revision of cases previously published. 10, 12, 13 This study reports the clinical characteristics and factors that influenced the prognosis of 67 patients with HIV and diagnosed R equi infection.
Materials and Methods
An observational, multicenter study was performed in 29 general hospitals from several regions in Spain. These hospitals comprised a total of 20,250 beds for acute patients and served a population of 9,716,880 inhabitants. All of the patients with HIV and R equi infection from the beginning of the AIDS epidemic until September 1998 were included. Information from every patient was collected by a previously designed form. The follow-up of each patient was carried out for as long as possible, and it was finished in December 1998. In those cases diagnosed before the beginning of this study, this information was collected retrospectively.
Isolation, identification, and susceptibility tests of the R equi strains were performed in the microbiology laboratory of each hospital. AIDS was diagnosed using the diagnostic criteria in force in Europe at the time of diagnosis of the R equi infection. 14 -16 Definitions Outcome of R equi Infection: This was assessed at the end of the follow-up period using three categories: cure, disappearance of the initial lesions and absence of manifestations of infection 1 month after withdrawing antimicrobial treatment; regression, reduction of the initial lesions and/or improvement of symptoms attributable to R equi infection during the course of antimicrobial therapy; and progression, increase of the lesions or exacerbation of symptoms attributable to R equi infection during the course of treatment, as well as the recurrence of infection after withdrawing treatment.
Survival: Survival was evaluated using the following categories: (1) death associated with R equi infection (related mortality), when the patient's death occurred due to causes directly attributable to the infection, to complications of the infection or to the therapy used; (2) death not associated with the infection, when death occurred with evidence of regression or cure of the infection and due to a cause not associated with the infection or its treatment; (3) and alive, when the patient was still alive at the last evaluation after the diagnosis of R equi infection.
Antibiotic Therapy: Antibiotic therapy was defined as appropriate when at least two active drugs were used against the causal agent and both during a period Ͼ 90 days. Treatment was considered as inappropriate in any other case.
Highly Active Antiretroviral Therapy (HAART): HAART was defined as the combination of two reverse transcriptase inhibitors with protease inhibitors for a period of Ͼ 30 days.
Statistical Analysis
A descriptive analysis of all the clinical characteristics collected from each patient was performed. Related mortality with R equi infection was considered to be the dependent variable for the analysis of the prognosis. The following variables were analyzed to know their possible association with related death: diagnosis of R equi infection before 1997, bacteremia, extrapulmonary location of the infection, multilobar pneumonia, previous or concomitant diagnosis of AIDS, CD4ϩ lymphocytes count, inappropriate antibiotic therapy, surgery, and absence of HAART. A statistically significant association was considered to exist when the p value was Ͻ 0.05. First, a univariate analysis was performed by means of the Cox proportional hazards method. Relative risks (RRs) and 95% confidence intervals (CIs) were calculated. Then, all the variables associated with related death in the univariate analysis were included in a multivariate Cox regression model, by means of a forward stepwise method, and contrasted by the likelihood ratio. Survival of patients with and without HAART was analyzed using the Kaplan-Meier method, and its statistical significance was assessed using the log-rank test.
Results
During the study period, 19,374 new patients received a diagnosis of AIDS in the participant hospitals. Sixty-seven patients with HIV received a diagnosis of R equi infection during 9 years (Fig 1) . Previous exposure to R equi was suspected in 10 patients. Mean Ϯ SD age was 31.7 Ϯ 5.8 years (range, 20 to 60 years), and most were male (55 patients, 82%). Risk activities for HIV infection were as follows: IV drug use, 48 patients (71.6%); heterosexual lifestyle, 11 patients (16.4%); bisexual or homosexual lifestyle, 3 patients (4.5%); transfusions, 2 patients (3%); blood derivatives, 1 patient (1.5%); and unknown, 2 patients (3%). Only eight of the patients who used IV drugs were still using IV drugs at the time of diagnosis of R equi infection.
The stage of HIV infection at the time of diagnosis of R equi infection was A3 in 7 patients (10.4%), B3 in 21 patients (31.3%), C3 in 38 patients (56.7%), and not clear in 1 patient (1.5%). The average CD4ϩ lymphocyte count was 35/L (range, 1 to 183/L). The most common symptoms attributable to R equi infection were fever (91%) and respiratory symptoms: cough (88.1%), expectoration (85.1%), and chest pain (44.8%) [ Table 1 ]. The average duration of symptoms before hospital admission was 47.7 Ϯ 48.6 days (range, 4 to 223 days). Most samples from which R equi was isolated were sputum (52.2%), blood cultures (50.7%), and samples from bronchoscopy (31.3%) [ Table 2 ]. Chest radiographic findings were abnormal in 65 patients (97%). Infiltrates were observed in all of them, and cavitations were observed in 45 patients. There was multilobar involvement in 13 patients, pleural effusions in 11 patients, and mediastinal lymphadenopathies in 2 patients. In patients in whom R equi infection was located in the lungs, the area involved was the upper right lobe in 20 patients, the middle lobe in 5 patients, the lower right lobe in 19 patients, the upper left lobe in 21 patients, and the lower left lobe in 18 patients. There was evidence of malakoplakia in tissue samples from five patients.
The mean follow-up period of patients after diagnosis of R equi infection was 10.7 Ϯ 12.8 months. Organs affected by R equi infection are shown in Table 3 . The lung was involved in 95.5% of episodes, and bacteremia was observed in 59.8%. Table 4 shows the antimicrobial susceptibility of strains that established the diagnosis of R equi infection. The most active antibiotics were vancomycin, amikacin, rifampicin, imipenem, ciprofloxacin, and erythromycin.
All but three patients received antibiotics for R equi infection. Eleven patients underwent surgery: lung resection (n ϭ 4) and drainage techniques (n ϭ 7). Twenty-four patients received HAART (35.8%), 42 patients (62.7%) did not receive HAART, and this information was unknown in 1 patient. The mean follow-up was 10.7 months. Regarding the outcome of R equi infection, 10 patients (14.9%) fulfilled the criteria for cure, and there was regression in 28 patients (41.8%) and progression in 29 patients (42.3%). Furthermore, after this period, 30 patients (44.8%) were still alive, 23 patients (34.3%) died due to causes related to R equi infection, and 14 patients (20.9%) died due to causes not related to the infection. Thus, 29 patients (43.3%) died in relation to R equi infection or presented evidence of progression. Table 5 shows the univariate analysis of the variables that were associated with the worst prognosis. These were multilobar involvement, absence of HAART, and inappropriate antimicrobial therapy for R equi infection. However, only the absence of HAART was independently associated with related mortality in the multivariate analysis (RR, 53.4; 95% CI, 1.7 to 1669). Figure 2 shows that the probability of death related to R equi infection among the 42 patients who did not receive HAART was much higher than that of the 24 patients who did. In fact, all the deaths for this reason occurred in patients who did not receive HAART.
Discussion
To our knowledge, this study describes the most extensive series published to date of R equi infection in patients with HIV. As this is a retrospective study, the data presented should be interpreted with caution and do not allow conclusions to be drawn on aspects that would require a previous homogeneous definition for all patients (for example, treatment used). However, we believe that this study furnishes information of interest, as it is a multicenter study carried out over a wide geographic area with a large population of patients with HIV infection. During the enrollment period of the 67 patients included in this study, 19,374 new cases of AIDS were diagnosed in the participant hospitals. This shows how uncommon this infection is, as well as the usefulness of a wide collection of cases in order to increase our knowledge about this process.
At the time of diagnosis of R equi infection, the average CD4ϩ lymphocyte count was very low. This fact shows that R equi induces disease in patients with HIV infection with advanced immunologic impairment and supports the opinion that R equi infection is considered an AIDS-defining event. 17 The most frequently involved organ was the lung, and this fact is a constant in the human infection. Thus, in two series of R equi infection with a total of 36 patients with HIV infection, the lung was involved in 91.7%. 12, 13 Furthermore, in a review of cases of patients without HIV infection, there was respiratory involvement in 27 of the 54 cases reported. 10 This justifies the fact that the clinical expression of the disease is mainly respiratory. In the present series, the lobes were involved with a similar frequency. Imaging techniques revealed pulmonary cavitations in two thirds of cases. In a series of 78 patients with HIV infection with pulmonary cavitations evaluated over a 7-year period, R equi was the causal agent in 7.7% of cases. 18 Therefore, R equi should form part of the differential diagnosis of cavitary pneumonia in patients with HIV infection. 19 As has already been pointed out, 12, 13 blood and sputum cultures were the samples with the best yield for the diagnosis of this infection. The pattern of antimicrobial susceptibility of the isolated strains is similar to that described in other studies, 13, 20 although this can vary in specific geographic areas 21 or in isolations with previous antibiotic therapy. 22, 23 Infection caused by R equi was a severe illness given that, after the follow-up period, more than one third of the patients died due to causes attributable to the infection and in a further 9% there were evidences of progression of the infection despite the prescribed treatment. When variables that influenced the prognosis of the patients were evaluated, only the absence of HAART was associated with R equi-related mortality. Moreover, no patients receiving HAART died in relation to the infection caused by R equi. It has been pointed out that the infection caused by R equi has a worse prognosis in patients with HIV than in patients without HIV, 24 and that they need a lifetime of antimicrobial therapy. 2, 24 However, a great change happened since HAART was introduced as standard therapy for HIV infection: there was a decrease in the incidence of opportunistic infections, 25 its prognosis improved, 26, 27 and secondary chemoprophylaxis could be suspended with no recurrences. 28, 29 It is likely that HAART can allow us to withdraw the antibiotic therapy at some time in patients with HIV and R equi infections, as well as to reduce the incidence of this opportunistic infection and, as could be observed in this study, to improve its prognosis. In fact, the outcome of patients included in this study was more favorable than that observed in other series with similar patients but which were carried out before HAART was available in clinical practice. 12, 13 The peculiar pathogenicity of R equi infection determines the treatment of this process. Due to the high frequency of bacteremia and high bacterial loads, it may be appropriate to indicate a combination of IV antibiotics with bactericidal effect such as imipenem plus vancomycin or imipenem plus teicoplanin. 30, 31 Lipophilic antibiotics with good intracellular penetration must then be administered, and combinations based on macrolides and rifampin have proven to be optimal. 1,2,13 Azithromycin seems to be an appropriate drug for the treatment of this infection in combination with others, as reaches high levels in tissues. 32 Appropriate antibiotic treatment did not influence outcomes in this study. This could be explained as the drugs that the patients received were very different from each other. This important issue could only be clarified by means of prospective studies, where homogeneous regimens are previously established. Drainage of abscesses must be carried out when possible; however, we think that resection surgery should be limited to selected patients who do not respond to medical treatment.
In summary, R equi infection is an uncommon opportunistic complication of HIV infection that occurs in advanced stages of immunodepression. It usually appears as a subacute pneumonia that is usually cavitary and bacteremic. Although the most effective antimicrobial therapy is unknown, taking into account the pathogenic and biological features of this organism, antimicrobial therapy should be based on a combination of drugs with a good intracellular penetration, and administered over a long period. Infection by R equi in patients with HIV is a severe illness although, as this study shows, HAART can improve its prognosis.
